RxDoctor Payments Data

John Streit, MD

Ophthalmology · Lubbock, TXNPI 1538262928

Payments from drug & device makers

$6,434in general payments, 2019–2025

Across 562 payments — averaging $11.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Bausch & Lomb Americas Inc.$1K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$602
  • Novartis$404
  • Sun Pharmaceutical Industries Inc.$349
  • Oyster Point Pharma, Inc.$236
  • plus $758 from 6 others

What the payments were for

  • Food & beverage$6,422100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,434 in reported general payments places this provider in the 75th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$288,469
Medicare patients
1,033
Services billed
3,701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost573$209,141
RestasisCyclosporine127$123,577
XiidraLifitegrast54$63,090
Bepotastine Besilate388$50,893
Cyclosporine96$48,728
Brimonidine Tartrate394$24,105
TyrvayaVarenicline Tartrate34$21,721
ProlensaBromfenac Sodium64$20,690
CombiganBrimonidine Tartrate/Timolol66$19,984
RhopressaNetarsudil Mesylate38$19,965
Alphagan PBrimonidine Tartrate79$19,898
VyzultaLatanoprostene Bunod45$18,292
Travoprost136$17,778
Epinastine Hcl203$15,768
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol147$14,751

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$2,972$372,600845 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo$1,113$92,667110 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Alrex, Bepreve, Loteprednol Etabonate$602$39,826133 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$113$30,11863 claims
Oyster Point Pharma, Inc.Tyrvaya$236$21,72134 claims
AlconSimbrinza$92$3,54614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →